Literature DB >> 3504264

Life-threatening tardive dyskinesia caused by metoclopramide.

M R Samie1, M A Dannenhoffer, S Rozek.   

Abstract

A case of severe life-threatening tardive dyskinesia resulting in esophageal and respiratory difficulties due to metoclopramide therapy is presented. A 66-year-old man with a primary diagnosis of clear cell carcinoma of the biliary duct was treated with metoclopramide for gastrointestinal symptoms related to his chemotherapy regimen. The patient initially presented with tremor and rigidity in the upper extremities. On antiparkinsonian therapy, symptoms progressed to hemiballism and involuntary movements of the face, mouth, and tongue, with respiratory and esophageal dyskinesia. Despite discontinuance of metoclopramide, severe tardive dyskinetic symptoms resulted in placement of a gastrostomy tube to maintain nutritional support. This case along with others in the literature should emphasize the need for continuous reevaluation of metoclopramide during long-term therapy, since serious side effects have been reported to occur.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3504264     DOI: 10.1002/mds.870020207

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  11 in total

1.  Tardive dyskinesia: therapeutic options for an increasingly common disorder.

Authors:  Leslie J Cloud; Deepti Zutshi; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

2.  Tardive dyskinesia.

Authors:  Pratibha G Aia; Gonzalo J Revuelta; Leslie J Cloud; Stewart A Factor
Journal:  Curr Treat Options Neurol       Date:  2011-06       Impact factor: 3.598

Review 3.  Movement disorder emergencies.

Authors:  Steven J Frucht
Journal:  Curr Neurol Neurosci Rep       Date:  2005-07       Impact factor: 5.081

4.  Laryngeal tardive dyskinesia.

Authors:  A Fève; B Angelard; J Lacau St Guily
Journal:  J Neurol       Date:  1995-07       Impact factor: 4.849

Review 5.  Movement disorder emergencies.

Authors:  Kathleen L Poston; Steven J Frucht
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

6.  Dysphagia in Huntington's disease: a 16-year retrospective.

Authors:  M C Kagel; N A Leopold
Journal:  Dysphagia       Date:  1992       Impact factor: 3.438

Review 7.  Oropharyngeal dysphagia due to iatrogenic neurological dysfunction.

Authors:  D W Buchholz
Journal:  Dysphagia       Date:  1995       Impact factor: 3.438

8.  Tardive Syndromes are Rarely Reversible after Discontinuing Dopamine Receptor Blocking Agents: Experience from a University-based Movement Disorder Clinic.

Authors:  Deepti Zutshi; Leslie J Cloud; Stewart A Factor
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2014-10-23

Review 9.  Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice.

Authors:  Robert A Hauser; Jonathan M Meyer; Stewart A Factor; Cynthia L Comella; Caroline M Tanner; Rose Mary Xavier; Stanley N Caroff; Leslie Lundt
Journal:  CNS Spectr       Date:  2020-11-20       Impact factor: 4.604

10.  NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.

Authors:  Christopher F O'Brien; Roland Jimenez; Robert A Hauser; Stewart A Factor; Joshua Burke; Daniel Mandri; Julio C Castro-Gayol
Journal:  Mov Disord       Date:  2015-09-08       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.